ClinicalTrials.gg
RecruitingNCT07203859Updated Jun 3, 2026

The Effectiveness of Quadro İliac Plane Block in Percutaneous Nephrolithotomies

An interventional study of Quadro-İliac Plane Block(QİPB) in Postoperative Pain and Percutaneous Nephrolithotomy, sponsored by Cumhuriyet University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Cumhuriyet University · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Our aim was to investigate the effect of quadro iliac plane block on postoperative analgesia in patients undergoing percutaneous nephrolithotomy surgery and to determine which areas of the skin this block anesthetizes.

02

Conditions studied

  • Postoperative Pain
  • Percutaneous Nephrolithotomy

Browse trials for

Keywords

  • postoperative pain
  • regional anesthesia
  • percutaneous nephrolithotomy
  • quadroiliac plane block
  • opioid free analgesia
  • ibuprofen
  • novel fascial plane block
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Cumhuriyet University is the lead sponsor of 133 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over 18 years of age who underwent percutaneous nephrolithotomy under general anesthesia and were I-II-III according to the (ASA) risk classification were included in the study.

Exclusion criteria

Exclusion Criteria:

  • patients who did not give consent,
  • patients with coagulopathy,
  • patients with signs of infection at the block application site,
  • patients using anticoagulants,
  • patients with known allergies to any of the study drugs,
  • patients with unstable hemodynamics,
  • patients who could not cooperate during postoperative pain assessment
  • patients who wanted to withdraw from the study,
  • patients with alcohol and drug addiction,
  • patients with musculoskeletal abnormalities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Control group

    No non-routine procedures will be performed on this group.

  • Active comparator
    Quadro-İliac Plane Block(QİPB)

    For this group, after the surgical procedure is completed, the patient will be placed in a lateral position with the operated side facing up, and a QIPB will be performed. With the patient in the lateral position, the spinous process of the L3 vertebra will first be imaged with an ultrasound probe positioned transversely in the midline. Then, by slightly shifting the probe laterally, the transverse process of the vertebra will be visualized within the erector spinae muscle. The probe will then be rotated in the sagittal plane and advanced caudally about 1 cm, visualizing the crista iliaca. On the cranial side of the crista iliaca, the erector spinae muscle, quadratus lumborum, and psoas major muscles will be visualized sequentially. With the needle direction cranial to caudal, the crista iliaca will be gently touched, and the needle will be positioned between the erector spinae and the quadratus lumborum muscle. After injecting 40 ml of 0.25% bupivacaine, the needle will be injected.

    Procedure: Quadro-İliac Plane Block(QİPB)

Interventions

  • ProcedureQuadro-İliac Plane Block(QİPB)

    40 mL of 0.25% bupivacaine

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS) Scores

    Description: Numerical rating scale is used for pain assessment. The scores of the numerical rating scale changes between 0 to 10 points. 10 points mean "the most severe pain that the patient ever had". 0 point means "there is no pain." Higher scores mean worse outcome.

    Time frame: Postoperative 24 hours

Secondary outcomes

  1. Dermatome Area

    Time frame: Postoperative 2 hours

  2. Total tramadol consumption

    Postoperative total analgesic need was recorded as "milligram" in unit.

    Time frame: Postoperative 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 11 months is close to that.

Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07203859
Responsible party
Oguz Gundogdu (Associate Professor, Cumhuriyet University) — Principal investigator
First posted
Oct 2, 2025
Start date
Sep 25, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

OĞUZ GÜNDOĞDU
Contact
droguzgundogdu@gmail.com
+905545945469
SAMET YENİHAN
Contact
samet_yenihan007@hotmail.com
OĞUZ GÜNDOĞDU
principal investigator · Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation
SAMET YENİHAN
study chair · Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion